Injection laryngoplasty was found to have favorable results in this group of patients with LC-1. Most patients experienced complete resolution of aspiration on MBS, and no patients experienced complications. These findings support the further study of injection laryngoplasty for LC-1 as both a diagnostic and therapeutic technique. Longer followup intervals are necessary to elucidate the predictive value with regard to success of formal cleft repair.
Bufalin extracts are a part of traditional Chinese medicine, Chansu. In the current study, we investigated the effect of bufalin on the proliferation of the human hepatocellular carcinoma (HCC) cell lines, Huh-7 and HepG-2, and explored the therapeutic potential of the drug. Our results demonstrated that bufalin markedly inhibited cell proliferation and promoted apoptosis in the Huh-7 and HepG-2 cells in vitro. The underlying mechanism of the bufalin-induced apoptosis was the induction of endoplasmic reticulum (ER) stress via the IRE1-JNK pathway. In addition, during the ER stress response, the autophagy pathway, characterized by the conversion of LC3-I to LC3-II, was activated, resulting in increased Beclin-1 protein levels, decreased p62 expression and stimulation of autophagic flux. Our data supported the pro-survival role of bufalin-induced autophagy when the autophagy pathway was blocked with specific chemical inhibitors; the involvement of the IRE1 pathway in the ER stress-induced autophagy was also demonstrated when the expression of IRE1 and CHOP was silenced using siRNA. These data indicate that combining bufalin with a specific autophagy inhibitor could be a promising therapeutic approach for the treatment of HCC.
Our data offer convincing evidence that miR-100 overexpression strongly associates with advanced tumor progression and unfavorable clinical outcome of patients with RCC. miR-100 expression may be a useful prognostic marker for this disease.
Low expression of miR-577 is related to the malignant clinicopathological features in HCC tissues, and miR-577 may suppress HCC growth through down-regulating β-catenin.
<p class="MsoNormal" style="text-align: left; margin: 0cm 0cm 0pt;" align="left"><span class="text"><span style="font-family: ";Arial";,";sans-serif";; font-size: 9pt;">Compared with conventional two-class learning schemes, one-class classification simply uses a single class in the classifier training phase. Applying one-class classification to learn from unbalanced data set is regarded as the recognition based learning and has shown to have the potential of achieving better performance. Similar to two-class learning, parameter selection is a significant issue, especially when the classifier is sensitive to the parameters. For one-class learning scheme with the kernel function, such as one-class Support Vector Machine and Support Vector Data Description, besides the parameters involved in the kernel, there is another one-class specific parameter: the rejection rate v. In this paper, we proposed a general framework to involve the majority class in solving the parameter selection problem. In this framework, we first use the minority target class for training in the one-class classification stage; then we use both minority and majority class for estimating the generalization performance of the constructed classifier. This generalization performance is set as the optimization criteria. We employed the Grid search and Experiment Design search to attain various parameter settings. Experiments on UCI and Reuters text data show that the parameter optimized one-class classifiers outperform all the standard one-class learning schemes we examined.</span></span><span style="font-family: ";Arial";,";sans-serif";; font-size: 9pt;"></span></p>
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.